酶免疫組化和酶聯(lián)免疫吸附試驗(yàn)在鼻咽癌普查中應(yīng)用比較
[Abstract]:Objective to investigate the value of enzyme immunohistochemical method (enzyme immunohistochemistry technique,IHCT) and enzyme-linked immunosorbent assay (enzyme linked immunosorbent assay,ELISA) in the screening of nasopharyngeal carcinoma (NPC) and to compare the results of the two methods. Methods in August 2013, the EB virus antigens (ELISA: VCA-IgA and EBNA1-IgA) of 3 843 healthy subjects were detected by enzyme immunohistochemical method and ELISA method respectively, and the stratified evaluation was made according to the level of EB virus antibody. Assessment: positive and negative groups (enzyme immunohistochemical method); high-risk groups, Middle risk group and low risk group (ELISA method). Results the positive rate of enzyme immunohistochemical method was 5.1% (P < 0.01). The positive rate of enzyme immunohistochemical method was 9.7% (374 / 3843). The positive rate of the two methods was positive in 53 cases. The difference was statistically significant (P0.01). Seven cases of nasopharyngeal carcinoma (NPC) were diagnosed in the Elisa positive group and the ELISA high risk group every 6 months until July 31, 2015. Among them, 6 cases were early nasopharyngeal carcinoma (T1~2N0M0). Nasopharyngeal carcinoma was not diagnosed in negative group, nasopharyngeal carcinoma was diagnosed in high risk group by ELISA method, 6 cases were diagnosed in middle risk group (positive group), and no nasopharyngeal carcinoma was found in low risk group (negative group) for 2 years. Conclusion ELISA method combined with enzyme immunohistochemical method is helpful to find early nasopharyngeal carcinoma and is more suitable for general examination of nasopharyngeal carcinoma.
【作者單位】: 廣西壯族自治區(qū)人民醫(yī)院耳鼻咽喉頭頸腫瘤科鼻咽癌研究所;廣西梧州市蒼梧縣鼻咽癌防治所;
【基金】:廣西科學(xué)研究與技術(shù)開發(fā)計(jì)劃項(xiàng)目(桂科攻14124003-3;桂科攻14279008)
【分類號】:R739.63
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 段建平,孫曉杰,常振華;免疫組化法對單純皰疹病毒腦炎早期診斷的意義[J];包頭醫(yī)學(xué)院學(xué)報(bào);2000年02期
2 任麗虹,,褚嘉佑,黃紹鏘,陳幼文,姚樹祥;免疫組化法檢測肺癌患者石蠟切片P~(53)蛋白的表達(dá)[J];云南醫(yī)藥;1996年01期
3 李小靜,孟剛,寧金龍,張林;免疫組化法對不同類型瘢痕微血管的定量研究[J];實(shí)用美容整形外科雜志;2000年04期
4 張澤松,李亞里,關(guān)錚,王立宏,劉愛軍;播散性腹膜平滑肌瘤病研究報(bào)告[J];中國現(xiàn)代醫(yī)學(xué)雜志;2001年12期
5 樓皖玲;潘家華;葛霞;姚敏;;免疫組化法觀察間質(zhì)性肺炎1例報(bào)告[J];工企醫(yī)刊;1999年01期
6 李建蓉;免疫組化法檢測HBsAg陰性乙型肝炎病毒感染的應(yīng)用價(jià)值[J];大理學(xué)院學(xué)報(bào)(醫(yī)學(xué)版);2002年01期
7 武正炎,杜競輝,毛力,王萱儀,范欽和,鄭肇巽,徐天蓉,夏開屏,張麗,槐魯寧;免疫組化法檢測乳腺癌患者骨髓內(nèi)轉(zhuǎn)移癌細(xì)胞[J];南京醫(yī)學(xué)院學(xué)報(bào);1989年02期
8 章金春,李芳秋,武建國;雙重酶免疫組化法識別淋巴細(xì)胞亞群中穿孔素的分布[J];醫(yī)學(xué)研究生學(xué)報(bào);2001年05期
9 劉志英;冬國友;;用免疫組化法檢測HER-2基因的質(zhì)控及意義[J];中國誤診學(xué)雜志;2008年21期
10 李坤;潘云燕;延俊元;楊香山;牛洪欣;;IDCA患者α1-AT表達(dá)水平及其與臨床病理因素相關(guān)性研究[J];中華腫瘤防治雜志;2014年11期
相關(guān)會議論文 前3條
1 薛天陽;許偉;安琪;沈桂芳;;兒童急性淋巴細(xì)胞白血病核轉(zhuǎn)錄因子-κB的表達(dá)及意義[A];中華醫(yī)學(xué)會第十四次全國兒科學(xué)術(shù)會議論文匯編[C];2006年
2 寧超;王競;鐘殿勝;王倩;馬晴;王小麗;劉暢;;特異性抗體免疫組化法檢測EGFR突變價(jià)值的meta分析[A];第13屆全國肺癌學(xué)術(shù)大會論文匯編[C];2013年
3 李冰;易正山;孟凡義;林榕;周淑蕓;;免疫組化法檢測外周血白細(xì)胞HCMV抗原方法學(xué)探討[A];第九屆全國實(shí)驗(yàn)血液學(xué)會議論文摘要匯編[C];2003年
本文編號:2270968
本文鏈接:http://sikaile.net/yixuelunwen/wuguanyixuelunwen/2270968.html